---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-001194"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:33:07.760965+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics prelim FY2025 global rev ~$616M; 2026 guided $875-900M

## Summary
- Preliminary FY2025 total global revenue ~$616M; U.S. BRIUMVI net product rev Q4 ~$182M, FY ~$594M.
- 2026 target total global revenue $875-900M; U.S. BRIUMVI net product rev $825-850M.
- 2026 operating expense target ~$350M (excl. SBC) + ~$100M for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up.
- Pipeline milestones: ENHANCE IV BRIUMVI trial data mid-2026; subcutaneous BRIUMVI topline year-end 2026/1Q 2027; azer-cel Phase 1 data in Progressive MS H2 2026.
- Plans to commence registration-directed trial for BRIUMVI outside MS and additional exploratory studies in autoimmune disease.

## SEC filing metadata
- accession: 0001437749-26-001194
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774926001194/0001437749-26-001194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774926001194/tgtx20260113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-001194
- JSON: https://secwatch.observer/filing/0001437749-26-001194.json
- Plain text: https://secwatch.observer/filing/0001437749-26-001194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.